Background: Taijin-kyofu (TK), especially the ‘convinced' subtype of TK (c-TK; also known as the ‘offensive' subtype of TK), is described as a Japanese culture-bound syndrome similar to social anxiety disorder (SAD). Recently, in Western countries, the symptoms of c-TK have been investigated in patients with SAD. We developed the Social Anxiety/Taijin-Kyofu Scale (SATS), a 12-item structured clinician-rated instrument designed to rate the severity of TK symptoms, and examined its reliability and validity. Methods: The SATS was administered to 15 patients with c-TK diagnosed using the traditional Japanese TK criteria. Interviews used to score patients' symptoms were recorded on videotape. Additionally, the Clinical Global Impression-Severity Scale (CGI-S) was administered to assess convergent validity. Interrater reliability was assessed on 15 videotaped interviews; the interviews were independently rated by 10 other raters. Test-retest re-liability was assessed on 15 videotaped interviews by the same rater at an interval of more than 4 weeks. Results: The SATS had high internal consistency (Cronbach's α = 0.97) and good interrater reliability (ICC = 0.88-0.93) and test-retest reliability (ICC = 0.94-0.99). The SATS total score correlated with the CGI-S scores (r = 0.77, p < 0.0001). Conclusion: The SATS appears to be a reliable and valid measure of the symptoms of TK.

Keywords:
Body dysmorphic disorder, Rating scale, Reliability, Social anxiety, Taijin-kyofu, Validity
1.
Kirmayer LJ: The place of culture in psychiatric nosology: Taijin Kyofusho and DSM-III-R. J Nerv Ment Dis 1991;179:19-28.
2.
Yamashita I: Taijin-kyofu or Delusional Social Phobia. Sapporo, Hokkaido University Press, 1993.
3.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
4.
Stein DJ, LeRoux L, Bouwer C, van Heerden B: Is olfactory reference syndrome an obsessive-compulsive spectrum disorder? Two cases and a discussion. J Neuropsychiatry Clin Neurosci 1998;10:96-99.
5.
Suzuki K, Takei N, Iwata Y, Sekine Y, Toyoda T, Nakamura K, Minabe Y, Kawai M, Iyo M, Mori N: Do olfactory reference syndrome and Jiko-Shu-Kyofu (a subtype of Taijin-Kyofu) share a common entity? Acta Psychiatr Scand 2004;109:150-155.
6.
Hollander E, Aronowitz BR: Comorbid social anxiety and body dysmorphic disorder: managing the complicated patient. J Clin Psychiatry 1999;60(suppl 9):27-31.
7.
Zimmerman M, Mattia JI: Body dysmorphic disorder in psychiatric outpatients: recognition, prevalence, comorbidity, demographic, and clinical correlates. Compr Psychiatry 1998;39:265-270.
8.
Wihelm S, Otto MW, Zucker BG, Pollack MH: Prevalence of body dysmorphic disorder in patients with anxiety disorders. J Anxiety Disord 1997;11:499-502.
9.
Veale D, Boocock A, Gournay K, Dryden W, Shah F, Willson R, Walburn J: Body dysmorphic disorder: a survey of fifty cases. Br J Psychiatry 1996;169:196-201.
10.
Gunstad J, Phillips KA: Axis I comorbidity in body dysmorphic disorder. Compr Psychiatry 2003;44:270-276.
11.
Coles ME, Phillips KA, Menard W, Pagano ME, Fay C, Weisberg RB, Stout RL: Body dysmorphic disorder and social phobia: cross-sectional and prospective data. Depress Anxiety 2006;23:26-33.
12.
Clarvist SR, Schneier FR, Liebowitz MR: The offensive subtype of Taijin-Kyofu-Sho in New York City: the phenomenology and treatment of a social anxiety disorder. J Clin Psychiatry 1996;57:523-527.
13.
Choy Y, Schneier FR, Heimberg RG, Oh KS, Liebowitz MR: Feature of offensive subtype of Taijin-Kyofu-Sho in US and Korean patients with DSM-IV social anxiety disorder. Depress Anxiety 2008;25:230-240.
14.
Kim J, Rapee RM, Gaston JE: Symptoms of offensive type Taijin-Kyofusho among Australian social phobics. Depress Anxiety 2008;25:601-608.
15.
Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708-713.
16.
Stein MB, Fyer AJ, Davidson JRT, Pollack MH, Wiita B: Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999;156:756-760.
17.
Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S, Pecknold JC, Hadrava V, Swinson RP: Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158:275-281.
18.
Liebowitz MR, Stein MB, Tancer ME, Carpenter D, Oakes R, Pitts CD: A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002;63:66-74.
19.
Liebowitz MR, Gelenberg AJ, Munjack D: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005;62:190-198.
20.
Kasper S, Stein DJ, Loft H, Nil R: Escitalopram in the treatment of social anxiety disorder: randomized, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005;186:222-226.
21.
Asakura S, Tajima O, Koyama T: Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2007;10:263-274.
22.
Phillips KA, Dwight MM, McElroy SL: Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 1998;59:165-171.
23.
Phillips KA, Albertini RS, Rasmussen SA: A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 2002;59:381-388.
24.
Phillips KA, Najjaf F: An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry 2003;64:715-720.
25.
Allen A, Hadley SJ, Kaplan A, Simeon D, Friedberg J, Priday L, Baker BR, Greenberg JL, Hollander E: An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectr 2008;13:138-144.
26.
Matsunaga H, Kiriike N, Matsui T, Iwasaki Y, Stein DJ: Taijin Kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors? Int J Neuropsychopharmacol 2001;4:231-237.
27.
Nagata T, Oshima J, Wada A, Yamada H, Iketani T, Kiriike N: Open trial of milnacipran for Taijin-Kyofusho in Japanese patients with social anxiety disorder. Int J Psychiatry Clin Pract 2003;7:107-112.
28.
Nagata T, Van Vliet I, Yamada H, Kataoka K, Iketani T, Kiriike N: An open trial of paroxetine for the ‘offensive subtype' of Taijin Kyofusho and social anxiety disorder. Depress Anxiety 2006;23:168-174.
29.
Liebowitz MR: Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-173.
30.
Asakura S, Inoue S, Sasaki F, Sasaki Y, Kikagawa N, Inoue T, Denda K, Ito M, Matsubara R, Koyama T: Reliability and validity of the Japanese version of the Liebowitz Social Anxiety Scale (in Japanese). Seishin Igaku (Clin Psychiatry) 2002;44:1077-1084.
31.
Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK: A severity rating scale for body dysmorphic disorder: development, reliability and validity of modified version of Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull 1997;33:17-22.
32.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Chamey DS: The Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Part I. Development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1012.
33.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Chamey DS: The Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Part II. Validity. Arch Gen Psychiatry 1989;46:1012-1016.
34.
Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA: Multicenter collaborative panic disorder severity scale. Am J Psychiatry 1997;154:1571-1575.
35.
Shear K, Belnap BH, Mazumdar S, Houck P, Rollman BL: Generalized anxiety disorder severity scale (GADSS): a preliminary validation study. Depress Anxiety 2006;23:77-82.
36.
Kasahara Y: Social phobia in Japan. Proc First Cultural Psychiatry Symp Japan Korea, Seoul, 1987, pp 3-14.
37.
Lee S: Social phobia in Korea. Proc First Cultural Psychiatry Symp Japan, Seoul, 1987, pp 24-52.
38.
Russell JG: Anxiety disorders in Japan: a review of the Japanese literature on Shinkeishitsu and Taijinkyofusho. Cult Med Psychiatry 1989;13:391-403.
39.
Takahashi T: Social phobia syndrome in Japan. Compr Psychiatry 1989;30:45-52.
40.
Nakamura K, Kitanishi K, Miyake Y, Hashimoto K, Kubota M: The neurotic versus delusional subtype of Taijin-Kyofu-Sho: their DSM diagnoses. Psychiatry Clin Neurosci 2002;56:595-601.
41.
Shear MK, Bilt JV, Rucci P, Endicott J, Lydi-ard B, Otto MW, Pollack MH, Chandler L, Williams J, Ali A, Frank DM: Reliability and validity of a structured interview for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety 2001;13:166-178.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.